Cantor Fitzgerald Brokers Lower Earnings Estimates for REGN

Key Points

• Cantor Fitzgerald has revised its FY2025 earnings per share (EPS) estimate for Regeneron Pharmaceuticals from $26.65 to $26.31, while also forecasting FY2026 earnings at $25.71 EPS.
• Regeneron reported a quarterly EPS of $12.89 on August 1st, significantly outperforming analyst predictions, with revenues reaching $3.68 billion for the quarter.
• The company's average stock rating remains at "Moderate Buy" with a consensus target price of $841.30, as a mix of institutions adjust their ratings.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) - Equities research analysts at Cantor Fitzgerald cut their FY2025 EPS estimates for Regeneron Pharmaceuticals in a note issued to investors on Monday, August 4th. Cantor Fitzgerald analyst C. Gould now anticipates that the biopharmaceutical company will post earnings per share of $26.31 for the year, down from their previous estimate of $26.65. Cantor Fitzgerald currently has a "Overweight" rating and a $695.00 price target on the stock. The consensus estimate for Regeneron Pharmaceuticals' current full-year earnings is $35.92 per share. Cantor Fitzgerald also issued estimates for Regeneron Pharmaceuticals' FY2026 earnings at $25.71 EPS.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $8.43 by $4.46. Regeneron Pharmaceuticals had a net margin of 31.37% and a return on equity of 15.06%. The company had revenue of $3,675,600 billion during the quarter, compared to analyst estimates of $3.30 billion. During the same quarter last year, the business posted $11.56 EPS. The company's revenue for the quarter was up 3.6% on a year-over-year basis.

A number of other research firms also recently weighed in on REGN. Argus downgraded Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Monday, June 30th. Guggenheim increased their price objective on Regeneron Pharmaceuticals from $810.00 to $815.00 and gave the stock a "buy" rating in a report on Friday, August 1st. Canaccord Genuity Group reiterated a "buy" rating and issued a $850.00 target price on shares of Regeneron Pharmaceuticals in a research note on Wednesday, July 23rd. Robert W. Baird decreased their target price on shares of Regeneron Pharmaceuticals from $759.00 to $652.00 and set a "neutral" rating for the company in a research report on Friday, April 25th. Finally, Wells Fargo & Company downgraded shares of Regeneron Pharmaceuticals from an "overweight" rating to an "equal weight" rating and set a $580.00 price target on the stock. in a report on Friday, August 1st. One analyst has rated the stock with a sell rating, seven have assigned a hold rating, sixteen have assigned a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, Regeneron Pharmaceuticals has an average rating of "Moderate Buy" and a consensus target price of $841.30.

Regeneron Pharmaceuticals Price Performance

Shares of NASDAQ:REGN opened at $555.13 on Thursday. The firm has a market cap of $59.93 billion, a price-to-earnings ratio of 13.99, a P/E/G ratio of 2.08 and a beta of 0.33. Regeneron Pharmaceuticals has a 1 year low of $476.49 and a 1 year high of $1,211.20. The company has a current ratio of 4.60, a quick ratio of 4.73 and a debt-to-equity ratio of 0.09. The business has a fifty day simple moving average of $536.31 and a 200 day simple moving average of $601.45.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, September 3rd. Shareholders of record on Monday, August 18th will be given a $0.88 dividend. The ex-dividend date is Monday, August 18th. This represents a $3.52 dividend on an annualized basis and a yield of 0.6%. Regeneron Pharmaceuticals's payout ratio is 8.87%.

Institutional Trading of Regeneron Pharmaceuticals

Large investors have recently added to or reduced their stakes in the company. Adirondack Trust Co. grew its position in Regeneron Pharmaceuticals by 4.2% during the 1st quarter. Adirondack Trust Co. now owns 451 shares of the biopharmaceutical company's stock worth $286,000 after acquiring an additional 18 shares during the last quarter. Kingswood Wealth Advisors LLC increased its stake in shares of Regeneron Pharmaceuticals by 1.8% in the first quarter. Kingswood Wealth Advisors LLC now owns 1,084 shares of the biopharmaceutical company's stock valued at $681,000 after buying an additional 19 shares in the last quarter. Creative Financial Designs Inc. ADV raised its holdings in shares of Regeneron Pharmaceuticals by 9.5% in the first quarter. Creative Financial Designs Inc. ADV now owns 220 shares of the biopharmaceutical company's stock valued at $139,000 after buying an additional 19 shares during the last quarter. Private Trust Co. NA lifted its position in Regeneron Pharmaceuticals by 13.1% during the 1st quarter. Private Trust Co. NA now owns 164 shares of the biopharmaceutical company's stock worth $104,000 after buying an additional 19 shares in the last quarter. Finally, Proficio Capital Partners LLC increased its position in Regeneron Pharmaceuticals by 6.2% in the 1st quarter. Proficio Capital Partners LLC now owns 327 shares of the biopharmaceutical company's stock valued at $207,000 after acquiring an additional 19 shares in the last quarter. 83.31% of the stock is owned by institutional investors.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.